{{Short description|Monoclonal antibody}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458270895 | type = mab | image = | alt = | mab_type = mab | source = u | target = integrin alpha-V | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category= | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 725735-28-4 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = GQE1BJE2NI | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D09631 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | C=6468 | H=10008 | N=1744 | O=2006 | S=40 }}
'''Intetumumab''' is a human monoclonal antibody targeting integrins<ref name="pmid30451118">{{cite journal | vauthors = Łasiñska I, Mackiewicz J | title = Integrins as A New Target for Cancer Treatment | journal = Anti-Cancer Agents in Medicinal Chemistry | volume = 19 | issue = 5 | pages = 580–586 | date = 2019 | pmid = 30451118 | doi = 10.2174/1871520618666181119103413 | s2cid = 53952455 }}</ref> that was being studied for the treatment of solid tumors.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=American Medical Association|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref>
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.<ref name="Adis">{{cite web|title=Intetumumab|url=http://adisinsight.springer.com/drugs/800019252|website=AdisInsight|access-date=30 January 2017}}</ref>
== References ==
<references />
{{monoclonals for tumors}}
Category:Janssen Biotech Category:Experimental cancer drugs
{{monoclonal-antibody-stub}} {{antineoplastic-drug-stub}}